Surveying The Landscape Of Bispecific Antibodies In Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Bispecific antibodies that can target two different disease antigens with one molecule come in many different formats and could be applied to a range of therapeutic areas. Oncology and inflammatory disease are at the forefront of clinical development (see related story, (Also see "Is The Time Finally Right For Bispecific Antibodies?" - Pink Sheet, 16 Apr, 2013.)).
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.